IFNA1 and myeloproliferative neoplasm: Combination therapy with IFN and ruxolitinib—a highly potent anti-inflammatory agent that induces a rapid decline in elevated inflammatory cytokines in concert with alleviation of constitutional symptoms—might also be an attractive approach, since this drug combination has displayed synergistic effects in MPN patients (Fig. 2) [68].